High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules

To estimate the BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma (PTC), and the diagnostic value of BRAFV600E mutation status in thyroid nodules with indeterminate TBSRTC categories. A total of 4875 consecutive samples for thyroid ultrasound-guided fine-needle aspiration cytology (FNAC) and BRAFV600E mutation analysis were collected from patients at Jiangsu Province Hospital on Integration of Chinese and Western Medicine. Among all the cases, 314 underwent thyroidectomy. According to TBSRTC categories, FNAC was performed for a preoperative diagnosis. ROC of the subject was constructed to evaluate the diagnostic value of these 2 methods and their combination. BRAFV600E mutation in FNAC of thyroid nodules occurred in 2796 samples (57.35%). Of 353 nodule samples from 314 patients with thyroid operation, 333 were pathologically diagnosed as PTC. Of these PTC patients, 292 (87.69%) were found to have BRAFV600E mutation in their preoperative FNAC. In 175 cytologically indeterminate thyroid nodules, BRAFV600E mutation identified 88% of PTC. According to ROC data, BRAFV600E mutation testing had an obviously higher sensitivity (87.69%) and specificity (100.00%) than TBSRTC. Combining BRAFV600E mutation testing and TBSRTC achieved the largest AUC (0.954). For 41 PTC with a negative BRAFV600E mutation in preoperative evaluation, the repeated BRAFV600E mutation testing found out 12 samples with BRAFV600E mutation. The true BRAFV600E mutation rate of Chi...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Diagnostic Accuracy Study Source Type: research